# Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

> **NCT01960374** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 117 (estimated)

## Conditions studied

- Healthy Volunteers Pharmacokinetic Study

## Interventions

- **DRUG:** Selumetinib

## Key facts

- **NCT ID:** NCT01960374
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2014-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01960374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01960374, "Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01960374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*